Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A method for the treatment of inflammatory arthritis (IA) in a human subject, comprising: orally administering to an individual in need of such treatment an effective amount of an active agent consisting of N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N^6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA;

wherein the effective amount is an amount which is less than a total daily dose of about ~~70~~ 114 microgram/Kg.

2-4 (Cancelled)

5 (Original). A method of Claim 1, wherein the active agent is administered once a day at a dose of less than about 5 mg.

6 (Previously Presented). A method of Claim 1, wherein the active agent is administered twice a day at a dose of less than about 57 microgram/Kg each dose.

7 (Original). A method of Claim 1, wherein the active agent is administered twice a day at a dose of less than about 4 mg each dose.

8 (Previously Presented). A method for the treatment of inflammatory arthritis (IA) in a human subject, comprising orally administering to an individual in need of such treatment an effective amount of N^6-(3-iodobenzyl)-

adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N^6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA), wherein the effective amount is an amount which is the human equivalent of a murine dose of 0.001 mg/Kg to 0.4 mg/Kg administered once or twice per day.

9 (Previously Presented). A method according to Claim 8, wherein the effective amount is an amount within the range of about 0.14 to about 57 microgram/Kg.

10 (Previously Presented). A method according to Claim 8, wherein the effective amount is within the range of about 0.01 to 4 mg.

11 (Previously Presented). A method according to Claim 8, wherein the effective amount is an amount within the range of about 0.14 to about 28 microgram/Kg.

12 (Previously Presented). A method according to Claim 8, wherein the effective amount is a dose within the range of about 0.01 to 2 mg.

13 (Previously Presented). A method according to Claim 8, wherein the effective amount is an amount within the range of about 1.4 to about 21 microgram/Kg.

14 (Previously Presented). A method according to Claim 8, wherein the effective amount is a dose within the range of about 0.1 to 1.5 mg.

15-27 (Cancelled)

28 (Previously Presented). A pharmaceutical composition for use in the treatment of a method according to any one of claims 1 and 5-14.